Bioventus acquires Misonix for $518M in cash & stock

By

websites: Bioventus and Misonix

Bioventus and Misonix Announce Definitive Agreement for Bioventus to Acquire Misonix (press release)
The Combination Further Differentiates Bioventus’ Product Portfolio and Accelerates Its Revenue Growth

Significantly Expands TAM and Adds Considerable Scale and Scope in Spine and Lower Extremity
Enhances Surgical Solutions Vertical by Adding Minimally Invasive Ultrasonic Technologies That Improve Clinical Outcomes
Deepens Restorative Therapies Vertical by Adding Regenerative Medicine Wound Products
Bioventus and Misonix Management to Host Joint C...

Get access to full posts newsletters, trends, and market reports for only subscribe for $1/day.
Hit the SUBSCRIBE button at the top of the homepage.